Parexel International Corp.

PRXL-Q

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about PRXL-Q

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
May 2, 2017

(A Top Pick March 23/16. Up 9%.) Does clinical trials for the major drug producers, which is about 75% of their business. It’s been mildly disappointing. A very good company. They are growing their cash, which may lead to a dividend being paid in the near future. Very active in buying back shares. It has lots of potential.

Show full opinionHide full opinion

(A Top Pick March 23/16. Up 9%.) Does clinical trials for the major drug producers, which is about 75% of their business. It’s been mildly disappointing. A very good company. They are growing their cash, which may lead to a dividend being paid in the near future. Very active in buying back shares. It has lots of potential.

TOP PICK
TOP PICK
March 23, 2016

A contract research organization that basically takes outsourced clinical studies on behalf of pharmaceuticals, runs the studies through various phases on behalf of them. They have $5.4 billion of backlog. Have just gone through a restructuring process which will be additive in the last half of this year to their earnings.

Show full opinionHide full opinion

A contract research organization that basically takes outsourced clinical studies on behalf of pharmaceuticals, runs the studies through various phases on behalf of them. They have $5.4 billion of backlog. Have just gone through a restructuring process which will be additive in the last half of this year to their earnings.

PAST TOP PICK
PAST TOP PICK
April 18, 2012
(A Top Pick April 27/11. Down 2.73%.) Contract research for Pharma companies. Very good company. Now going into partnership with large pharmas.
Show full opinionHide full opinion
(A Top Pick April 27/11. Down 2.73%.) Contract research for Pharma companies. Very good company. Now going into partnership with large pharmas.
PAST TOP PICK
PAST TOP PICK
March 14, 2012
(Top Pick Apr 27/11, Down 5.79%) Clinical trial company. It is an efficient model
Show full opinionHide full opinion
(Top Pick Apr 27/11, Down 5.79%) Clinical trial company. It is an efficient model
TOP PICK
TOP PICK
April 27, 2011
Clinical trial management. They take phase 1 drugs and run them through the trials. About a $2.9 billion backlog and a book to bill of about $1.5 billion, meaning that for every $1 they bill, they get orders of $1.50.
Show full opinionHide full opinion
Clinical trial management. They take phase 1 drugs and run them through the trials. About a $2.9 billion backlog and a book to bill of about $1.5 billion, meaning that for every $1 they bill, they get orders of $1.50.
PAST TOP PICK
PAST TOP PICK
March 10, 2010
(A Top Pick March 11/09. Up 180.8%.) About 60% of revenues come from outside the US.
Show full opinionHide full opinion
(A Top Pick March 11/09. Up 180.8%.) About 60% of revenues come from outside the US.
PAST TOP PICK
PAST TOP PICK
February 17, 2010
(Top Pick Mar 11/09, Up 163.6%) Not as cheap as it was, but still good value.
Show full opinionHide full opinion
(Top Pick Mar 11/09, Up 163.6%) Not as cheap as it was, but still good value.
TOP PICK
TOP PICK
March 11, 2009
Contract research organization and do drug trials on behalf of pharmaceuticals and biopharmas. Stock has been beaten down on worries of lack of pipeline and foreign exchange worries.
Show full opinionHide full opinion
Contract research organization and do drug trials on behalf of pharmaceuticals and biopharmas. Stock has been beaten down on worries of lack of pipeline and foreign exchange worries.
TOP PICK
TOP PICK
July 9, 2008
Contract research that does clinical drug trials for major drug companies. Strong growing franchise.
Show full opinionHide full opinion
Contract research that does clinical drug trials for major drug companies. Strong growing franchise.
Showing 1 to 9 of 9 entries
  • «
  • 1
  • »

Parexel International Corp.(PRXL-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Parexel International Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Parexel International Corp.(PRXL-Q) Frequently Asked Questions

What is Parexel International Corp. stock symbol?

Parexel International Corp. is a OTC stock, trading under the symbol PRXL-Q on the (). It is usually referred to as or PRXL-Q

Is Parexel International Corp. a buy or a sell?

In the last year, there was no coverage of Parexel International Corp. published on Stockchase.

Is Parexel International Corp. a good investment or a top pick?

Parexel International Corp. was recommended as a Top Pick by Gordon Reid on 2017-05-02. Read the latest stock experts ratings for Parexel International Corp..

Why is Parexel International Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Parexel International Corp. worth watching?

In the last year, there was no coverage of Parexel International Corp. published on Stockchase.

What is Parexel International Corp. stock price?

On , Parexel International Corp. (PRXL-Q) stock closed at a price of $.